Journals / Turkish Journal of Medical Sciences / 2021 / Cilt: 51 - Sayı: 2

Early detection breast cancer: role of circulating plasma miRNA-21 expression as a potential screening biomarker

Pages
562–569
Publication Date
2022-11-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Circulating miRNA-21 expression is a potential biomarker for early detection of breast cancer and might act as a breast cancer risk predictor.Key words: Biomarkers, breast neoplasms, diagnosis, human plasma, miRNA-21

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aim: To explore the potential of the circulating plasma miRNA-21 as an early detection biomarker by comparing earlystage breast cancer (BG) and healthy control (HG) in Indonesian population.
📊
Key Findings & Data:Materials and methods: The enlisted patients were 26 adult female early-stage breast cancer patients (stage 1A, 1B, 2A, and 2B) of Airlangga University Hospital from August 2019 to October 2019.
💡
Conclusion & Impact:Conclusion: Circulating miRNA-21 expression is a potential biomarker for early detection of breast cancer and might act as a breast cancer risk predictor.Key words: Biomarkers, breast neoplasms, diagnosis, human plasma, miRNA-21
🔬Design:Research Article
📍Scope:2019 Verileri
⚙️Variables:Domain Parameters

Abstract

Background/aim: To explore the potential of the circulating plasma miRNA-21 as an early detection biomarker by comparing earlystage breast cancer (BG) and healthy control (HG) in Indonesian population. Materials and methods: The enlisted patients were 26 adult female early-stage breast cancer patients (stage 1A, 1B, 2A, and 2B) of Airlangga University Hospital from August 2019 to October 2019. Sixteen volunteers were recruited as matching healthy subjects. MiRNA-21 expression was quantified by plasma qRT-PCR. Data analysis performed using IBM SPSS Statistics v.24 (IBM Corp., Armonk, NY, USA). MiRNA-21 cut-off, sensitivity, and specificity were analyzed using receiver operating characteristic (ROC) curve. Results: The study included 26 BG and 16 HG subjects. The miRNA-21 expression in BG group was 3.933 (1.181-11.794) and 0.905 (0.164-4.532) in HG group (4.34 folds; P = 0.001), with 1.66 cut-off (92.3% sensitivity; 81.2% specificity). MiRNA-21 expression separated analysis in HG showed a 0.578 times lower expression in menopause subjects [0.651 (0.164-0.414)], compared to premenopause ones [(1.123 (0.758 - 4.532); P = 0.031]. Yet, in BG group, 1.729 times higher miRNA-21 expression was observed in menopause subjects (6.021 ± 3.583), compared to premenopause ones (3.500 ± 1.517; P = 0.022). Conclusion: Circulating miRNA-21 expression is a potential biomarker for early detection of breast cancer and might act as a breast cancer risk predictor.Key words: Biomarkers, breast neoplasms, diagnosis, human plasma, miRNA-21

🔖

Cite This Article

WIJAYA, A. Y., HENDRATA, W. M., DIANSYAH, M. N., PRAYOGO, A. A., SEDANA, M. P., SAVITRI, M., ROMADHON, P. Z., AMRITA, P. N. A., BINTORO, U. Y. (2022). Early detection breast cancer: role of circulating plasma miRNA-21 expression as a potential screening biomarker. Turkish Journal of Medical Sciences, Cilt: 51 - Sayı: 2, 562–569. https://ajindex.com/articles/609589

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Zhu W, Harvey S, Macura KJ, Euhus DM, Artemov D. Invasive breast cancer preferably and predominantly occurs at the interface between fibroglandular and adipose tissue. Clinical Breast Cancer 2017
  2. 17 (1): e11-e18. doi: 10.1016/j. clbc.2016.07.009 2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians 2018
  3. 68 (6): 394-424. doi: 10.3322/caac.21492 3. Kharkwal S, Sameer A, Mukherjee A. Triple test in carcinoma breast. Journal of Clinical and Diagnostic Research 2014
  4. 8 (10): NC09–NC11. doi: 10.7860/JCDR/2014/9237.4971 4. Perakis S, Speicher MR. Emerging concepts in liquid biopsies. BioMed Central Medicine 2017
  5. 15 (1): 75. doi: 10.1186/ s12916-017-0840-6 5. Heywang-Köbrunner SH, Hacker A, Sedlacek S. Advantages and disadvantages of mammography screening. Breast Care 2011
  6. 6 (3): 199-207. doi: 10.1159/000329005 6. Guo R, Lu G, Qin B, Fei B. Ultrasound imaging technologies for breast cancer detection and management: a review. Ultrasound in Medicine and Biology 2018
  7. 44 (1): 37-70. doi: 10.1016/j. ultrasmedbio.2017.09.012 7. Ng EKO, Li R, Shin VY, Jin HC, Leung CPH et al. Circulating microRNAs as specific biomarkers for breast cancer detection. Public Library of Science One 2013
  8. 8 (1): e53141. doi: 10.1371/ journal.pone.0053141 8. Gao J, Zhang Q, Xu J, Guo L, Li X. Clinical significance of serum miR-21 in breast cancer compared with CA153 and CEA. Chinese Journal of Cancer Research 2013
  9. 25 (6): 743- 748. doi: 10.3978/j.issn.1000-9604.2013.12.04 9. Uehara M, Kinoshita T, Hojo T, Akashi-Tanaka S, Iwamoto E et al. Long-term prognostic study of carcinoembryonic antigen (CEA) and carbohydrate antigen 15-3 (CA 15-3) in breast cancer. International Journal of Clinical Oncology 2008
  10. 13 (5): 447-451. doi: 10.1007/s10147-008-0773-3 10. Pan X, Wang Z-X, Wang R. MicroRNA-21: A novel therapeutic target in human cancer. Cancer Biology and Therapy 2010
  11. 10 (12): 1224-1232. doi: 10.4161/cbt.10.12.14252 11. Iorio M V, Croce CM. Causes and consequences of microRNA dysregulation. The Cancer Journal 2012
  12. 18 (3): 215-222. doi: 10.1097/PPO.0b013e318250c001 12. Rani GSBS, Bitla AR. Breast cancer diagnosis – role of biomarkers. Journal of Clinical and Scientific Research 2017
  13. 6 (4): 225-236. doi: 10.15380/2277-5706.JCSR.17.08.005 13. Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Kerin MJ. MicroRNAs as novel bio